DAVENPORT & Co LLC Sells 186,412 Shares of Kenvue Inc. $KVUE

DAVENPORT & Co LLC lowered its position in shares of Kenvue Inc. (NYSE:KVUE) by 47.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 205,607 shares of the company’s stock after selling 186,412 shares during the period. DAVENPORT & Co LLC’s holdings in Kenvue were worth $3,349,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of KVUE. Vanguard Group Inc. lifted its position in Kenvue by 1.8% in the 2nd quarter. Vanguard Group Inc. now owns 233,246,267 shares of the company’s stock worth $4,881,844,000 after buying an additional 4,101,880 shares during the last quarter. Geode Capital Management LLC grew its position in Kenvue by 1.2% during the second quarter. Geode Capital Management LLC now owns 49,001,887 shares of the company’s stock valued at $1,021,267,000 after acquiring an additional 604,953 shares during the last quarter. Independent Franchise Partners LLP raised its stake in shares of Kenvue by 233.4% during the second quarter. Independent Franchise Partners LLP now owns 31,265,574 shares of the company’s stock worth $654,388,000 after acquiring an additional 21,886,537 shares in the last quarter. American Century Companies Inc. lifted its holdings in shares of Kenvue by 38.6% in the 2nd quarter. American Century Companies Inc. now owns 30,265,020 shares of the company’s stock worth $633,447,000 after acquiring an additional 8,436,166 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of Kenvue in the 2nd quarter worth approximately $537,418,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Stock Performance

Shares of NYSE:KVUE opened at $17.20 on Friday. The company has a current ratio of 0.98, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The company has a 50-day moving average price of $16.44 and a 200-day moving average price of $18.73. The company has a market cap of $32.95 billion, a price-to-earnings ratio of 22.93 and a beta of 0.60. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $25.17.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Monday, November 3rd. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. The company had revenue of $3.76 billion for the quarter, compared to the consensus estimate of $3.83 billion. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.Kenvue’s revenue was down 3.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.28 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, equities analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, November 26th. Stockholders of record on Wednesday, November 12th were paid a dividend of $0.2075 per share. The ex-dividend date of this dividend was Wednesday, November 12th. This represents a $0.83 annualized dividend and a dividend yield of 4.8%. Kenvue’s payout ratio is 110.67%.

Insider Activity at Kenvue

In other Kenvue news, Director Jeffrey C. Smith bought 3,200,000 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The stock was bought at an average price of $17.37 per share, for a total transaction of $55,584,000.00. Following the completion of the acquisition, the director directly owned 27,307,632 shares in the company, valued at $474,333,567.84. The trade was a 13.27% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.68% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts recently commented on KVUE shares. Johnson Rice reaffirmed a “neutral” rating on shares of Kenvue in a report on Tuesday, October 28th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Kenvue in a research note on Tuesday, October 14th. Evercore ISI set a $18.00 price objective on Kenvue in a report on Tuesday, October 28th. Rothschild & Co Redburn upgraded Kenvue from a “neutral” rating to a “buy” rating and dropped their target price for the company from $22.50 to $22.00 in a report on Friday, September 26th. Finally, UBS Group reduced their price target on Kenvue from $23.00 to $17.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and twelve have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $20.23.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.